Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Deferred Tax Liabilities: $4,397M in Q3 2026, up 102.5% from a year earlier.
Latest, Q3 2026
4,397
Period ended Sep 30, 2026
Change on a year earlier
+102.5%
2,171 in Q3 2025
History
35 quarters
Since Q4 2016
Sources
33
Documents cited below
Where the Q3 2026 figure comes from
“|| Deferred tax liabilities | 4 397 | 3 397”
Source: Novartis Form 6-K (0001114448-26-000014) ↗
Reported in Postgres DB + Form 6-K.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Novartis Deferred Tax Liabilities ($M), quarterly Q4 2016–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/db-bs-dtl
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.